BIOMARK's Health Canada Submission Update

(TheNewswire)

Vancouver, British Columbia / TheNewswire / February 21, 2018 – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to provide an update on its Health Canada submission progress following data analysis on its clinical trial activities.

Listed below are new accomplishments over the past 2 weeks:

1. BioMark’s regulatory team at St. Boniface Hospital Research Centre and the assigned biostatistician have completed detailed data analysis and tabulation on clinical trials based in Canada and Bangladesh.
2.A comprehensive medical follow up report of the outliers in both in Canada and Bangladesh has been reviewed by Dr. Andrew Maksymiuk, the Principal Investigator at CancerCare Manitoba along with our regulatory team members from St. Boniface Hospital Research Centre. Initial assessment report of the outliers demonstrates BioMark SSAT1 technology can provide physicians an economical diagnostic tool to effectively pre-screen patients for either more expensive CT screening or more invasive biopsy procedure. (Outliers are subjects who were considered healthy but exhibited higher than expected Acetyl Amantadine concentrations). An ongoing follow up will serve as part of our surveillance and strengthen the clinical applicability of our data.
3.Compilation of the package to be filed with Health Canada has begun and a team has been assembled to accelerate the submission.

Next Steps
News will be released as soon as the submission package is completed in the next couple of weeks.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions, which can help, detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-307-0779

Email: [email protected]

Copyright (c) 2018 TheNewswire - All rights reserved.

Disclaimer :: Use of this site is subject to, and your continued use constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information. INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion; however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment. Users should always consult with and obtain advice from their professional licensed financial advisor, including their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment or trading securities do so with caution. Users should perform full due diligence and investigate any security fully before making an investment or before the execution of a security trade based upon information learned through INK. Investors should obtain annual reports and other company information to complete their own due diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this website. On this site, there may be third party content, content from authors or links to third-party sites or pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI® is a registered trade-mark owned by the Alberta Securities Commission.Read less

Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.

Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.